AVEO Pharmaceuticals, Inc. (AVEO)

[Biotech Pharmer]

Tivozanib will pass ODAC and be granted FDA approval for refractory RCC. The deal has been structured to save Padzur's face after his vindictiveness 7 years ago against prior management who bucked his NDA recommendation. By going for the 2nd/3rd/4th lines this time, it has paved the way for easy approval. Sora passed the FDA because it was the first of it's kind and was only going against a placebo. It's now the flip phone of RCC treatment. The jewel of Tivozanib will be the combination therapies that are evolving across all lines. The drug works....and it works really really well, with less toxicities and twice the effective response rate as Sora. Thoughtful and insightful info like this is available on StockTwits by MesaBoogie who has a nice grasp on the topic. Or you could listen to the child here that LOL's all of the time about his crew from Mom's basement. You make the call.